Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines

Garattini, S; Bertele, V

Garattini, S (reprint author), Ist Ric Farmacol Mario Negri, IRCCS, Via Giuseppe La Masa 19, I-20156 Milan, Italy.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018; 74 (3): 373

Abstract

Consideration of drug benefits and harms is asymmetric. Approval of drugs is mainly based on efficacy, while the assessment of their safety is left to......

Full Text Link